Market Overview

UPDATE: Aegis Capital Reiterates on Cancer Genetics Following Better-Than-Expected 3Q 2013 Financial Results

Related CGIX
Cancer Genetics, Inc. Receives New York State Licensure for FHACT Cervical Cancer Test
Cancer Genetics Inc Receives Second Patent For Genomic Cervical Cancer Test; Strengthens Position Of FHACT

In a report published Thursday, Aegis Capital Corp. analyst Raghuram Selvaraju reiterated a Buy rating on Cancer Genetics (NASDAQ: CGIX), and raised the price target from $25.00 to $32.50.

In the report, Aegis Capital Corp. noted, “Yesterday afternoon, after the market close, Cancer Genetics reported financial results for the third quarter of 2013. The firm reported a loss per share of $0.61, well below the $0.94 that we had originally projected. Revenue beat our estimate of $1.6mm, coming in at $1.7mm, and test volumes rose over 70% from the year-ago equivalent period, reaching 2,920 samples processed. Given the beat on both top- and bottom-line levels and the solid expense control, we are impressed with the operational performance to date. The firm recently raised gross proceeds of $46mm from the sale of ~3.3mm shares at $14.00 per share, in a registered direct equity offering that was led by Aegis Capital Corp. as sole book runner. Given the solid cash position, which we project as $50mm pro forma, and given near-term potential for sales and marketing infrastructure expansion, we reiterate our Buy rating and raise our price target from $25.00 to $32.50 per share with a 12-month time frame. In our view, Cancer Genetics represents a highly differentiated investment opportunity, given its broad pipeline of marketed and development-stage tests, and with its ability to generate high-margin revenue from partnerships with biopharmaceutical firms seeking to develop theranostic solutions for patients.”

Cancer Genetics closed on Wednesday at $12.60.

Latest Ratings for CGIX

Apr 2015Janney CapitalInitiates Coverage onBuy
Aug 2014Cantor FitzgeraldMaintainsBuy
Apr 2014Cantor FitzgeraldInitiates Coverage onBuy

View More Analyst Ratings for CGIX
View the Latest Analyst Ratings

Posted-In: Aegis Capital Corp. Raghuram SelvarajuAnalyst Color Price Target Analyst Ratings


Related Articles (CGIX)

Around the Web, We're Loving...